Abstract
Aim: To assess the therapeutic benefits of Maximum Androgen Blockade and the Tolerability of Bicalutamide, an oral non-steroidal anti-androgen in patients with advanced prostate cancer. Patients and Methods: A total of forty-nine(49) male patients aged between 42 and 84 years with tumour grades T 2 , T 3 and T 4 were enrolled in a multi-centre clinical trial to receive bicalutamide 50mg daily following surgical castration. Patients were assessed for disease status, adverse events and quality of life. Results: Thirty-three (33) patients completed the study and had therapy for 48 weeks, 90.9% of whom had complete response while the quality of life due to urinary symptoms was also markedly improved. The profile of adverse events was mild. Conclusion: Bicalutamide given as a daily dose of 50mg in combination with surgical castration is a well tolerated therapy and has therapeutic benefits in African patients with advanced prostate cancer. Key Words: Advanced Prostate Cancer, Surgical Castration, Bicalutamide, Tolerability, Thera-peutic Benefits, Maximum Androgen Blockade. Journal of College of Medicine 2005: 9(2): 72-76
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
